Bulletin
Investor Alert

Repligen Corp.

NAS: RGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 30, 2021, 7:00 p.m.

/zigman2/quotes/210324360/composite

$

244.21

Change

-1.49 -0.61%

Volume

Volume 24,616

Quotes are delayed by 20 min

/zigman2/quotes/210324360/composite

Previous close

$ 241.00

$ 245.70

Change

+4.70 +1.95%

Day low

Day high

$239.04

$248.25

Open

52 week low

52 week high

$138.00

$248.25

Open

Company Description

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downs...

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Valuation

P/E Current

220.96

P/E Ratio (with extraordinary items)

139.62

P/E Ratio (without extraordinary items)

172.33

Price to Sales Ratio

28.20

Price to Book Ratio

6.86

Price to Cash Flow Ratio

159.89

Enterprise Value to EBITDA

90.94

Enterprise Value to Sales

26.99

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

324,699.00

Income Per Employee

53,126.00

Receivables Turnover

6.37

Total Asset Turnover

0.22

Liquidity

Current Ratio

2.83

Quick Ratio

2.53

Cash Ratio

2.25

Profitability

Gross Margin

53.06

Operating Margin

22.19

Pretax Margin

16.17

Net Margin

16.36

Return on Assets

3.63

Return on Equity

4.63

Return on Total Capital

5.20

Return on Invested Capital

4.17

Capital Structure

Total Debt to Total Equity

18.01

Total Debt to Total Capital

15.26

Total Debt to Total Assets

14.47

Long-Term Debt to Equity

1.73

Long-Term Debt to Total Capital

1.46

Officers and Executives

Name Age Officer Since Title
Mr. Tony J. Hunt 55 2014 President, Chief Executive Officer & Director
Mr. Jim Bylund - 2020 Senior Vice President-Global Operations & IT
Mr. Jon K. Snodgres 53 2014 Secretary, Chief Financial & Accounting Officer
Mr. Ralf Kuriyel 60 2016 Senior Vice President-Research & Development
Mr. Kola Otitoju - - Senior VP-Strategy & Business Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/20/2021 Karen T. Dawes
Director
614   Disposition at $203.11 per share. 124,709
07/20/2021 Karen T. Dawes
Director
2,877   Disposition at $202.29 per share. 581,988
07/20/2021 Karen T. Dawes
Director
806   Disposition at $201.37 per share. 162,304
07/20/2021 Karen T. Dawes
Director
288   Disposition at $200.01 per share. 57,602
07/13/2021 Karen T. Dawes
Director
5   Disposition at $204.02 per share. 1,020
07/13/2021 Karen T. Dawes
Director
444   Disposition at $203.09 per share. 90,171
07/13/2021 Karen T. Dawes
Director
630   Disposition at $202.29 per share. 127,442
07/13/2021 Karen T. Dawes
Director
441   Disposition at $201.27 per share. 88,760
07/13/2021 Karen T. Dawes
Director
2,929   Derivative/Non-derivative trans. at $41.19 per share. 120,645
07/13/2021 Karen T. Dawes
Director
2,929   Derivative/Non-derivative trans. at $41.19 per share. 120,645
07/13/2021 Karen T. Dawes
Director
1,520   Disposition at $202.23 per share. 307,389
06/10/2021 Ralf Kuriyel
Senior VP, R&D
6,802   Disposition at $189.19 per share. 1,286,870
06/10/2021 Ralf Kuriyel
Senior VP, R&D
1,045   Derivative/Non-derivative trans. at $86.1 per share. 89,974
06/10/2021 Ralf Kuriyel
Senior VP, R&D
2,557   Derivative/Non-derivative trans. at $59.52 per share. 152,192
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
380   Disposition at $175.15 per share. 66,557
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
2,819   Disposition at $174.41 per share. 491,661
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
1,560   Disposition at $173.19 per share. 270,176
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
3,036   Disposition at $172.52 per share. 523,770
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
3,420   Disposition at $171.32 per share. 585,914
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
7,911   Disposition at $170.28 per share. 1,347,085
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
2,529   Disposition at $169.45 per share. 428,539
05/19/2021 Tony J. Hunt
Chief Executive Officer; Director
612   Disposition at $168.29 per share. 102,993
05/14/2021 Christine Gebski
See Remarks
445   Disposition at $172.25 per share. 76,651
05/14/2021 Jon K. Snodgres
Chief Financial Officer
470   Disposition at $172.6 per share. 81,122
05/14/2021 Ralf Kuriyel
Senior VP, R&D
710   Disposition at $172.29 per share. 122,325
05/13/2021 Karen T. Dawes
Director
604   Award at $0 per share. 0
05/13/2021 Glenn P. Muir
Director
457   Award at $0 per share. 0
05/13/2021 Thomas F. Ryan
Director
457   Award at $0 per share. 0
05/13/2021 Nicolas M. Barthelemy
Director
457   Award at $0 per share. 0
05/13/2021 Carrie Eglinton Manner
Director
457   Award at $0 per share. 0
05/13/2021 Rohin Mhatre
Director
457   Award at $0 per share. 0
05/11/2021 Karen T. Dawes
Director
285   Disposition at $176.85 per share. 50,402
05/11/2021 Karen T. Dawes
Director
15,000   Derivative/Non-derivative trans. at $3.22 per share. 48,300
04/06/2021 James R. Bylund
SVP, Global Operations & IT
360   Disposition at $204.25 per share. 73,530
03/16/2021 Christine Gebski
See Remarks
1,400   Disposition at $196.88 per share. 275,632
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
235   Disposition at $194.08 per share. 45,608
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
227   Disposition at $193.3 per share. 43,879
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
1,378   Disposition at $192.17 per share. 264,810
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
1,081   Disposition at $191.19 per share. 206,676
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
4,096   Disposition at $190.17 per share. 778,936
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
1,171   Disposition at $188.77 per share. 221,049
03/12/2021 Tony J. Hunt
Chief Executive Officer; Director
914   Disposition at $188.06 per share. 171,886
03/12/2021 Thomas F. Ryan
Director
170   Gift at $0 per share. 0
/news/latest/company/us/rgen

MarketWatch News on RGEN

  1. How a 53-Year-Old Growth Fund Takes the Long View

    9:30 p.m. July 30, 2021

    - Barron's Online

  2. Repligen started at overweight with $241 stock price target at KeyBanc Capital

    8:03 a.m. Nov. 10, 2020

    - Tomi Kilgore

  3. Small-Cap ‘Darlings’ Are Perking Up in 2020

    11:47 a.m. Jan. 21, 2020

    - Barron's Online

  4. These 6 stocks in the S&P 1500 have more than doubled in 12 months

    7:28 a.m. July 13, 2019

    - Philip van Doorn

  5. Repligen started at overweight with $42 stock price target at J.P. Morgan

    8:28 a.m. Dec. 5, 2017

    - Tomi Kilgore

  6. Repligen stock fair value estimate raised to $47 from $42 at Janney

    11:26 a.m. June 23, 2017

    - Tomi Kilgore

  7. Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln

    7:01 a.m. June 23, 2017

    - Tomi Kilgore

  8. Repligen's stock halted for news pending

    6:58 a.m. June 23, 2017

    - Tomi Kilgore

  9. Repligen's stock was inactive premarket prior to trading halt

    6:59 a.m. June 23, 2017

    - Tomi Kilgore

  10. Investing From the Ground Up

    12:13 a.m. Sept. 15, 2016

    - Barron's Online

  11. Why Danaher’s Purchase of Pall Means More M&A is on the Way

    11:39 a.m. May 13, 2015

    - Barrons Blogs

  12. Bull trend absorbs soft second-quarter start

    10:41 a.m. April 6, 2015

    - Michael Ashbaugh

  13. These are the most profitable Nasdaq biotech companies

    12:36 p.m. March 2, 2015

    - Philip van Doorn

  14. Here are the best-performing stocks so far in 2015

    12:47 p.m. Jan. 9, 2015

    - Philip van Doorn

  15. Loading more headlines...
/news/nonmarketwatch/company/us/rgen

Other News on RGEN

  1. Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

    11:16 a.m. July 30, 2021

    - Zacks.com

  2. Why Repligen Stock Soared This Week

    6:11 a.m. July 30, 2021

    - Motley Fool

  3. BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance

    2:17 p.m. July 29, 2021

    - Zacks.com

  4. Company News for Jul 28, 2021

    9:35 a.m. July 28, 2021

    - Zacks.com

  5. 10-Q: REPLIGEN CORP

    4:55 p.m. July 27, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. Repligen Corp (RGEN) Q2 2021 Earnings Call Transcript

    2:00 p.m. July 27, 2021

    - Motley Fool

  7. Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

    12:38 p.m. July 27, 2021

    - Zacks.com

  8. Repligen shares rise on Q2 earnings beat, FY forecast raise

    7:56 a.m. July 27, 2021

    - Seeking Alpha

  9. Repligen Q2 Earnings Preview

    1:31 p.m. July 26, 2021

    - Seeking Alpha

  10. Notable earnings before Tuesday's open

    10:08 a.m. July 26, 2021

    - Seeking Alpha

  11. 3 Healthcare Stocks to Buy and Hold for the Next 10 Years

    6:15 a.m. July 22, 2021

    - Motley Fool

  12. Loading more headlines...

At a Glance

Repligen Corp.

41 Seyon Street

Building 1

Suite 100

Waltham, Massachusetts 02453

Phone

1 7812500111

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$366.26M

Net Income

$59.93M

2020 Sales Growth

35.5%

Employees

1,128

/news/pressrelease/company/us/rgen

Press Releases on RGEN

  1. Chromatography Resin Market Trends and Forecast 2028

    5:14 a.m. July 23, 2021

    - Market Insight Reports

  2. Loading more headlines...
Link to MarketWatch's Slice.